Trusted Resource for Clinical Trials, Protocols & Progress
Bioavailability and bioequivalence (BA/BE) studies are essential for establishing the therapeutic equivalence of generic drugs to their reference products. Two primary designs dominate BA/BE protocols: parallel design and crossover design. Each has unique applications, advantages, and regulatory expectations.
Click to read the full article.
Bioavailability (BA) and bioequivalence (BE) studies are critical for demonstrating that a generic product performs similarly to its innovator counterpart in terms of drug absorption and bioavailability. Regulatory agencies such as the FDA, EMA, CDSCO, and Health Canada require robust study designs to ensure confidence in these assessments. The two most frequently used designs in BA/BE are the parallel and crossover designs, each offering distinct advantages depending on the pharmacokinetic profile, therapeutic index, and regulatory constraints.
Click to read the full article.
In bioavailability and bioequivalence (BA/BE) studies, the accuracy of pharmacokinetic (PK) parameters heavily depends on the subject population. Unlike large-scale efficacy trials, BA/BE studies focus on assessing the rate and extent of drug absorption, typically under controlled conditions. Selecting an appropriate study population is therefore crucial—not only for scientific accuracy but also to comply with regulatory expectations.
Click to read the full article.
In bioequivalence (BE) trials, the decision to conduct a single-dose or multiple-dose study impacts not only the study duration and complexity but also its scientific validity and regulatory acceptance. The key objective of a BE study is to demonstrate that the Test and Reference formulations exhibit comparable pharmacokinetics (PK). How many doses are administered—and under what conditions—can significantly affect PK parameters such as Cmax, AUC0–t, and Tmax.
Click to read the full article.
In clinical research, the terms open-label and blinded describe whether trial participants, investigators, or assessors know which treatment is being administered. In bioavailability and bioequivalence (BA/BE) studies, the question of blinding isn’t always straightforward. While efficacy trials commonly require blinding to minimize bias, BA/BE studies—especially pharmacokinetic evaluations—often rely on objective endpoints like plasma drug concentrations, raising the question: Is blinding necessary?
Click to read the full article.
Bioequivalence (BE) studies are crucial for ensuring that a generic formulation matches its reference product in pharmacokinetic performance. However, certain drugs exhibit high intra-subject variability in key pharmacokinetic parameters such as Cmax and AUC, even when administered under controlled conditions. These drugs are classified as Highly Variable Drug Products (HVDPs), generally defined by a coefficient of variation (CV%) exceeding 30%.
Click to read the full article.
In bioavailability and bioequivalence (BA/BE) development, the journey from formulation development to regulatory submission typically involves two key study types: the pilot study and the pivotal study. While both aim to assess pharmacokinetics and bioequivalence, their roles, design expectations, and regulatory weight differ significantly.
Click to read the full article.
Bioequivalence (BE) studies are essential in establishing the interchangeability of generic and innovator drug products. While standard two-period, two-sequence crossover designs are common in BA/BE studies, they may not be sufficient for Highly Variable Drug Products (HVDPs) or specific regulatory needs. In such cases, replicate crossover designs offer a scientifically robust and regulatory-compliant alternative.
Click to read the full article.
Modified Release (MR) formulations, including sustained release (SR), extended release (ER), and controlled release (CR), provide distinct therapeutic advantages such as reduced dosing frequency and minimized side effects. However, demonstrating bioequivalence (BE) for MR formulations presents additional challenges compared to immediate-release (IR) products.
Click to read the full article.
In bioavailability and bioequivalence (BA/BE) studies using a crossover design, the washout period plays a critical role in ensuring study integrity. The washout is the interval between two dosing periods during which the drug administered in the first period is expected to be sufficiently eliminated from the body before the second period begins. An inadequate washout can lead to carryover effects, jeopardizing the validity of pharmacokinetic (PK) comparisons and leading to regulatory rejection.
Click to read the full article.
